Tag Archive for: FDA
Coronavirus and Cancer Resources for Survivors
Cancer survivors have expressed concerns and questions about COVID-19, the coronavirus, and how they may be at higher risk due to their cancer history. Here are some resources about COVID-19 generally, and its impact for cancer survivors specifically. NCCS is seeking answers from public health experts on the coronavirus and its impact on cancer patients and survivors. Please leave a comment [...]
WCOE: Replacing the SGR Formula, Patient Advocate Speaks at FDA, and Dr. Peter Ubel talks Patient Needs
https://twitter.com/CancerAdvocacy/status/585110117261189120
https://twitter.com/MBCNbuzz/status/584062316418834432
https://tw…
WCOE: Pace of FDA Drug Approvals, Redesigning Insurance Exchanges, Shared Decision Making, and Thoughts on Data Collection
https://twitter.com/ResearchAmerica/status/570688447880556544
https://twitter.com/sfuldnasso/status/570389151532646401
https:/…
NCCS Policy Comments: FDA’s Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)
NCCS submitted comments to the Food and Drug Administration (FDA) on the Draft Guidance: Framework for Regulatory Oversight of Laboratory…
Announcing a New Blog Series: “The Imperatives for Quality Cancer Care” 20 Years Later
Read posts from the new blog series: "The Imperatives for Quality Cancer Care" 20 Years Later
In 1995, NCCS published Imperatives…
WCOE: New IOM Report, Control Issues, Tempting Treatment Options, and Patients ‘Right to Try’ New Drugs
https://twitter.com/theIOM/status/555428756106805249
https://twitter.com/CancerAdvocacy/status/555477303653044224
https://twit…
WCOE: FDA News, Medical Debt, the ACA, and Honoring Jessie Gruman
https://twitter.com/ElaineSchattner/status/553203989940928512
https://twitter.com/KaiserFamFound/status/553214546643808256
htt…
NCCS Policy Comments: Recommending Cancer Survivorship as a Topic for FDA Patient-Focused Drug Development Meetings
Last week, NCCS submitted comments to the U.S. Food and Drug Administration (FDA) regarding the series of patient-focused drug development…
NCCS Offers Policy Comments: Strategies for Increasing Patient Participation in FDA Review Activities
The Food and Drug Administration Safety and Innovation Act (FDASIA) authorized a patient-focused drug development program, and in the…
WCOE: Brittany Maynard’s Death with Dignity, Election Results and the ACA, and Susan Gubar’s “Not Talking About Medical Mistakes”
Brittany Maynard, a 29-year-old woman with brain cancer who became an advocate for the “death with dignity” movement took her…
Incremental Improvements Are Not Enough
Two years ago, the world lost an extraordinary person, my dear friend Dr. Brent Whitworth. He was a few days shy of his 42nd birthday…